Drugs / HPV 16 E7:12-20 Peptide Vaccine
last change Sep 2013 re-read 2 minutes ago

HPV 16 E7:12-20 Peptide Vaccine

Vaccine

Developed for
cutaneous melanoma
Investigated by
National Cancer Institute (NCI)

Trials 1 · a red edge is where a trial was stopped

2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT01989559 Oct 2002 → Sep 2013 cutaneous melanoma National Cancer Institute (NCI) Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as HPV 16 E7:12-20 Peptide Vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT01989559
Modality Vaccine “HPV 16 E7:12-20 peptide vaccineNCT01989559
Route Subcutaneous “Given SC” NCT01989559